medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2011, Número 05-06

<< Anterior Siguiente >>

Medicina & Laboratorio 2011; 17 (05-06)


Guía de atención de la fiebre amarilla
Ministerio de la Protección Social

Idioma: Español
Referencias bibliográficas: 41
Paginas: 247-264
Archivo PDF: 858.91 Kb.


FRAGMENTO

La fiebre amarilla es la primera de las enfermedades hemorrágicas virales reconocidas en el mundo, siendo una entidad de gran interés en salud pública por su potencial epidémico y su alta letalidad, además de ser evitable mediante vacunación y controlable por medio de acciones regulares a partir de los sistemas de vigilancia. Se trata de una zoonosis de regiones tropicales que ha causado varias epidemias con elevada mortalidad. Los únicos continentes donde ocurre en forma endémica son África y América del Sur, lugares donde ocasiona hasta 200.000 casos anualmente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Monath T. Yellow fever: an update. The Lancet Infectious Diseases Vol 1 August 2001: 11-20.

  2. República de Colombia. Ministerio de Salud. Decreto 412 de 2000. Guía de atención fiebre amarilla. 2000.

  3. ASCOFAME ISS. Guía de práctica clínica basada en la evidencia. Dengue y fiebre amarilla 1998.

  4. Kish MA. Guide to Development of Practice Guidelines. Clinical Infectious Diseases 2001; 32: 851-4.

  5. Jovell AJ, Navarro-Rubio MD. Evaluación de la evidencia científica. Med Clin (Barc) 1995; 105: 740-743.

  6. OPS/OMS. Control de la fiebre amarilla. Guía práctica. Publicación científica 603. Washington, 2005.

  7. Ministerio de Salud, Servicio de erradicación de la malaria, Instituto Nacional de Salud. Fiebre Amarilla en la Sierra Nevada de Santa Marta: Estudio y control de una epidemia. Imprenta del Servicio de erradicación de la malaria. Bogotá, Marzo 1980.

  8. Vega A. Fiebre amarilla: a propósito de la alerta. MedUNAB 2004; 7: 15-20.

  9. Rodríguez G. Velandia MP, Boshell J. Fiebre amarilla la enfermedad y su control, Instituto Nacional de Salud, Bogotá 2003.

  10. Vargas MA. Virología Médica. Universidad Nacional de Colombia, 2002.

  11. Ministerio de la Protección Social, Instituto Nacional de Salud. Informe Quincenal Epidemiológico Nacional. Volumen 9, Número 10. Mayo 30 de 2004.

  12. Jones M, Wilson D. Clinical features of yellow fever cases at Vom Christian Hospital during the epidemic on the Jos Plateau, Nigeria. Bulletin of the World Health Organization 1972; 46: 63-5.

  13. Monath T. Yellow fever: a medically neglected desease. Report on a seminar. Rev Infect Dis 1987; 9: 165-75.

  14. Benenson A. OPS/OMS. Manual para el control de las enfermedades transmisibles. Publicación Científica 564. Decimosexta edición. 1997: 188-92.

  15. Kerr J. The clinical aspects and diagnosis of yellow fever. In, Strode G, editor, Yellow Fever. NY/McGraw-Hill, 1951: 29-40.

  16. Monath T, Nasidi A. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg 1993; 48: 74-9.

  17. Miot HA, Batistella RF, Batista KDA. Comparative study of the topical effectiveness of the Andiroba oil (Carapa guianensis) and DEET 50% as repellent for Aedes sp. Revista do Instituto de Medicina Tropical de Sao Paulo. 2004; 46 (5): 253-6.

  18. Pfister M, Kürsteiner O, Hilfiker H, et al. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. The American journal of tropical medicine and hygiene. 2005; 72 (3): 339-46.

  19. Belmusto-Worn VE, Sánchez JL, McCarthy K, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. The American journal of tropical medicine and hygiene. 2005; 72 (2): 189-97.

  20. Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. The American journal of tropical medicine and hygiene. 2002; 66 (5): 533-41.

  21. Osei-Kwasi M, Dunyo SK, Koram KA, et al. Antibody response to 17D yellow fever vaccine in Ghanaian infants. Bulletin of the World Health Organization 2001; 79 (11): 1056-9.

  22. Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. The American journal of tropical medicine and hygiene 1999; 60 (6): 1045-50.

  23. Roche JC, Jouan A, Brisou B. Comparative clinical study of a new 17D thermostable yellow fever vaccine. Vaccine. 1986; 4 (3): 163-5.

  24. Ministerio de la Protección Social, Programa Nacional de Salud, 2002-2006. Bogotá: 2003.

  25. WHO, “Global Advisory Committee on Vaccine Safety (2-3 December 2004)”. Wkly Epidemiol Rec. 2005; 80 (1): 3-7.

  26. Jennings A, Gibson C, Millar L, el al. Análisis of a yellow fever virus isolated from a fatal case of vaccine associated human encephalitis. J Infect Dis 1994; 169: 512-8.

  27. Osinusi K, Akinkugbe FM, Akinwolere OA, Fabiyi A. Safety and efficacy of yellow fever vaccine in children less thanone-year-old. West African journal of medicine. 1990; 9(3): 200-3.

  28. Stefano I, Sato HK, Pannuti CS. Recent immunization against measles does not interfere with the seroresponse to yellow fever vaccine. Vaccine. 1999; 17 (9-10) : 1042-6.

  29. Adu FD, Omotade OO, Oyedele OI, Ikusika O. Field trial of combined yellow fever and measles vaccines among children in Nigeria. East African medical journal 1996; 73 (9): 579-82.

  30. Lhuillier M, Mazzariol MJ, Zadi S. Study of combined vaccination against yellow fever and measles in infants from six to nine months. Journal of biological standardization; 1989; 17 (1): 9-15.

  31. Kollaritsch H, Que JU, Kunz C, Wiedermann G, Herzog C, Cryz SJ. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. The Journal of infectious diseases. 1997; 175 (4): 871-5.

  32. Robert E, Vial TB, Schaefer CS. Exposure to yellow fever vaccine in early pregnancy. Vaccine 1999; 17: 283 - 285.

  33. Tattevin P et al. Yellow fever vaccine is safe and effective in HIV infected patients. aids 18: 825-827, 2004.

  34. Kitchner S. Viscerotropic and neurotropic disease following vaccination with the yellow fever 17D vaccine ARILVAX. Vaccine 2004: 2103-5.

  35. Cetron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, et al. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR 2002; 51 (RR-17): 1-11.

  36. Kirkpatrick BD, Alston WK. Current immunizations for travel. Tropical and travelassociated diseases. Curr Opin Infect Dis 2003; 16: 369-74.

  37. Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination: United States, 2001-2002. MMWR 2002; 51: 989-93.

  38. Martin M, Tsai T, Cropp B, et al. Fever and multisystem organ failure associated with 17D yellow fever vaccine in Brazil: a report of two cases. The Lancet 2001; 358: 98-104.

  39. Deubel V, Huerre M, Cathomas G, Drouet MT, Wuscher N, Le Guenno B, et al. Molecular detection and characterization of yellow fever virus in blood and liver specimens of a non-vaccinated fatal human case. J Med Virol 1997; 53: 212-7.

  40. Saluzzo J-P, Monath TP, Cornet M. Comparison de différent techniques virologiques pour la détection du virus de fièvre jaune dans les prélêvements humains et des lots de moustiques. Intêrét d’une methode rapide de diagnostic par ELISA. Ann Inst Past Virol 1985; 136E: 115-29.

  41. Leontsini E, Gil E, Kendall C, Clark GG. Effect of a community-based Aedes aegypti control programme on mosquito larval production sites in El Progreso, Honduras. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1993; 87 (3): 267-71.




2020     |     www.medigraphic.com